ストックスクリーナーアプリを入手
28.02
0.57%
0.16
前日終値:
$27.86
開ける：
$27.77
24時間の取引高:
1.68M
Relative Volume:
1.04
時価総額：
$4.83B
収益：
$1.10B
当期純損益:
$375.65M
株価収益率:
12.76
EPS:
2.1963
ネットキャッシュフロー:
$113.59M
1週間 パフォーマンス:
-3.74%
1か月 パフォーマンス:
+3.20%
6か月 パフォーマンス:
+19.79%
1年 パフォーマンス:
+9.88%
1日の値動き範囲:
$27.65
$28.19
1週間の範囲:
$27.61
$29.75
52週間の値動き範囲:
$19.69
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
名前
Acadia Pharmaceuticals Inc
セクター
電話
858-558-2871
住所
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
28.02 | 5.00B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-02-23 | アップグレード | Mizuho | Neutral → Outperform |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-05-21 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2025-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | 開始されました | BMO Capital Markets | Outperform |
| 2024-03-12 | ダウングレード | Mizuho | Buy → Neutral |
| 2024-03-12 | 繰り返されました | Needham | Buy |
| 2024-01-30 | 開始されました | Robert W. Baird | Outperform |
| 2024-01-24 | アップグレード | Needham | Hold → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2023-12-13 | 開始されました | Citigroup | Buy |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-11-06 | アップグレード | Mizuho | Neutral → Buy |
| 2023-10-17 | 開始されました | UBS | Buy |
| 2023-10-10 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-01-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-11-04 | ダウングレード | Goldman | Neutral → Sell |
| 2022-11-01 | 開始されました | Loop Capital | Hold |
| 2022-08-08 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-08-05 | ダウングレード | Citigroup | Buy → Neutral |
| 2022-06-21 | ダウングレード | Jefferies | Buy → Underperform |
| 2022-06-16 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-16 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | アップグレード | Citigroup | Neutral → Buy |
| 2021-12-21 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-11-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-06-10 | 開始されました | Berenberg | Hold |
| 2021-04-07 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | ダウングレード | Goldman | Buy → Neutral |
| 2021-04-06 | ダウングレード | Jefferies | Buy → Hold |
| 2021-04-06 | ダウングレード | Mizuho | Buy → Neutral |
| 2021-04-05 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-03-09 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-03-09 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-03-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-03-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | ダウングレード | Stifel | Buy → Hold |
| 2020-12-16 | 開始されました | Mizuho | Buy |
| 2020-11-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | 開始されました | Raymond James | Outperform |
| 2020-08-20 | 開始されました | Morgan Stanley | Overweight |
| 2020-07-07 | アップグレード | Stifel | Hold → Buy |
| 2020-04-16 | 開始されました | Jefferies | Buy |
| 2020-03-31 | アップグレード | Goldman | Neutral → Buy |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2019-12-16 | 開始されました | Guggenheim | Buy |
| 2019-10-24 | 開始されました | Oppenheimer | Perform |
| 2019-10-01 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-09-13 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | 繰り返されました | Needham | Buy |
| 2018-12-10 | 開始されました | Canaccord Genuity | Hold |
| 2018-09-21 | アップグレード | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | 繰り返されました | Stifel | Hold |
| 2018-08-07 | 開始されました | Stifel | Hold |
| 2018-08-06 | ダウングレード | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
すべてを表示
Acadia Pharmaceuticals Inc (ACAD) 最新ニュース
Virtus Advisers LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Great Lakes Advisors LLC Purchases New Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits New 1-Year HighHere's What Happened - MarketBeat
Rice Hall James & Associates LLC Purchases Shares of 618,887 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Stronger 2026 Outlook After Mixed Q2 Results Might Change The Case For Investing In ACAD (ACAD) - simplywall.st
UBS raises Acadia Pharmaceuticals stock price target on trial optimism By Investing.com - Investing.com Australia
ACAD Maintained by UBS -- Price Target Raised to $49.00 - GuruFocus
UBS raises Acadia Pharmaceuticals stock price target on trial optimism - Investing.com
GSA Capital Partners LLP Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Makes New Investment in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACAD Stock Eyes Best Day In Over A Year As CHMP Recommends Approval For Rare Nerve Disorder Drug In Europe - Stocktwits
48,794 Shares in ACADIA Pharmaceuticals Inc. $ACAD Purchased by State of Wyoming - MarketBeat
Assenagon Asset Management S.A. Sells 57,075 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Bank of America Corp DE Acquires 332,325 Shares of ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals Inc. Stock 12‑Month Price Target Cut to $33.05, Implies 17% Upside - TradingView
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
STATE STREET CORP Adds to ACADIA Pharmaceuticals Inc (ACAD) Stak - GuruFocus
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Canaccord reiterates Acadia Pharmaceuticals stock rating on products By Investing.com - Investing.com Canada
Canaccord reiterates Acadia Pharmaceuticals stock rating on products - Investing.com India
Royal Bank of Canada Trims Stock Holdings in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Analysts Offer Insights on Healthcare Companies: Elanco Animal Health (ELAN) and ACADIA Pharmaceuticals (ACAD) - The Globe and Mail
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline - Investing.com India
ACADIA Pharmaceuticals Expands DAYBUE, NUPLAZID Reach Ahead of Key Alzheimer’s Data - MarketBeat
Acadia Pharmaceuticals at Canaccord Genuity conference: growth, pipeline By Investing.com - Investing.com Nigeria
ACAD: DAYBUE STIX is quickly overtaking the original formulation as European launch preparations advance - TradingView
Acadia Pharmaceuticals stock hits 52-week high at $29.81 - Investing.com
Acadia Pharmaceuticals stock hits 52-week high at $29.81 By Investing.com - Investing.com Australia
ACADIA Pharmaceuticals (NASDAQ:ACAD) Gains Fresh Market Attention - Kalkine Media
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $41.00 Price Target at Needham & Company LLC - MarketBeat
ACAD Maintains Buy Rating by Needham -- Price Target Raised to $41 - GuruFocus
Needham Maintains ACADIA Pharmaceuticals(ACAD.US) With Buy Rating, Raises Target Price to $41 - Moomoo
Acadia Pharmaceuticals (ACAD) Q2 2026 Earnings Call Transcript - AOL.com
ACADIA Pharmaceuticals Inc. (ACAD) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Hits Fresh High: What Now? - Kalkine Media
Morgan Stanley Adjusts PT on ACADIA Pharmaceuticals to $27 From $26, Maintains Equalweight Rating - Moomoo
Janus Henderson Group PLC Decreases Stake in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) Reaches New 52-Week HighWhat's Next? - MarketBeat
Acadia Pharmaceuticals to Gain From Daybue, Nuplazid Growth; RADIANT Data Adds Risk, Morgan Stanley Says - Moomoo
Immunic appoints Elena Ridloff to board of directors - Yahoo Finance
ACAD Maintained by Citigroup -- Price Target Raised to $39.00 - GuruFocus
ACADIA Pharmaceuticals Inc. Revenue Breakdown – BIVA:ACAD - TradingView
Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Empowered Funds LLC Purchases Shares of 48,982 ACADIA Pharmaceuticals Inc. $ACAD - MarketBeat
Results: ACADIA Pharmaceuticals Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates - simplywall.st
Acadia CFO Mark Schneyer sells $587k in company stock - Investing.com
Acadia CFO Mark Schneyer sells $587k in company stock By Investing.com - Investing.com Canada
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded to Buy at Wall Street Zen - MarketBeat
Mark Schneyer Sells 5,849 Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock - MarketBeat
Acadia Pharmaceuticals Inc (ACAD) 財務データ
収益
当期純利益
現金流量
EPS
Acadia Pharmaceuticals Inc (ACAD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Option Exercise |
17.84 |
5,849 |
104,346 |
73,677 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 06 '26 |
Sale |
29.22 |
14,292 |
417,604 |
67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Sale |
29.00 |
5,849 |
169,638 |
67,828 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):